• Kenneth B Chapman, Matthew A Spiegel, Noud van Helmond, Kiran V Patel, Ajax Yang, Tariq A Yousef, Nataniel Mandelberg, Timothy Deer, and Alon Y Mogilner.
• The Spine & Pain Institute of New York, New York, NY, USA; Department of Anesthesiology, NYU Langone Medical Center, New York, NY, USA; Department of Anesthesiology, Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA. Electronic address: chapmanken@spinepainny.com.
• Neuromodulation. 2022 Oct 1; 25 (7): 1024-1032.

IntroductionSpinal cord stimulation (SCS) can provide long-term pain relief for various chronic pain conditions, but some patients have no relief with trial stimulation or lose efficacy over time. To "salvage" relief in patients who do not respond or have lost efficacy, alternative stimulation paradigms or anatomical targets can be considered. Dorsal root ganglion stimulation (DRG-S) has a different mechanism of action and anatomical target than SCS.ObjectivesWe assessed DRG-S salvage therapy outcomes in patients who did not respond to SCS or had lost SCS efficacy.Materials And MethodsWe retrospectively included consecutive patients from 2016 to 2020 who were salvaged with DRG-S after failed SCS trials (<50% pain reduction) or who had lost efficacy after permanent SCS. We compared numerical rating scale (NRS) pain, Oswestry disability index (ODI), health-related quality of life (EuroQol five-dimensions five-level), and oral morphine equivalent (OME) opioid requirements before DRG-S salvage and at patients' last follow-up.ResultsA total of 60 patients who had failed SCS were salvaged with DRG-S. The mean age was 56 ± 12 years, and the most common diagnoses were complex regional pain syndrome (n = 24) and failed back surgery syndrome (n = 24). The most common failed modalities included tonic (n = 32), Burst (n = 18), and high-frequency (n = 10) SCS. The median follow-up duration of salvage DRG-S was 34 months. With DRG-S, NRS decreased (8.7 ± 1.2 to 3.8 ± 2.1), and OME declined (median 23 mg to median 15 mg), whereas EuroQol 5D scores increased (0.40 ± 0.15 to 0.71 ± 0.15), and ODI improved (64 ± 14% to 31 ± 18%) (all p < 0.05).ConclusionsDRG-S can be used in patients with chronic pain who have previously failed to receive persistent benefit from SCS.Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

22 keywords...

hide…